Cancer

CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE

BEIJING, July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare…

2 years ago

Koning Health Brings Advanced Breast Imaging Technology to Bedford Breast Center in Beverly Hills

BEVERLY HILLS, Calif., July 11, 2024 /PRNewswire/ -- Koning Health is excited to announce the upcoming installation of its innovative Koning…

2 years ago

Induced Pluripotent Stem Cells Market Size is Expected to Grow at a CAGR of 9.4% and Reach USD 4.6 billion by 2034: Transparency Market Research Inc.

Induced pluripotent stem cells are experiencing strong growth due to rising research into disease models and drug discovery.  WILMINGTON, Del. ,…

2 years ago

Lucid Diagnostics Launches New Corporate Website

NEW YORK, July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics…

2 years ago

Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening

Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and…

2 years ago

Element Biosciences Raises Over $277 Million to Develop and Commercialize Differentiated Products and Continue Rapid Growth

SAN DIEGO, July 11, 2024 /PRNewswire/ -- Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced over $277…

2 years ago

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract – Now 12-Month Data

CARDIFF, UK / ACCESSWIRE / July 11, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company developing a…

2 years ago

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas TherapeuticsFirst instance decision on…

2 years ago

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in…

2 years ago

Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham 

Beckham becomes a strategic investor in PreneticsBeckham and Prenetics are co-founding partners for IM8, a new health and wellness brand…

2 years ago